PURPOSE: Oral anticoagugulants (OACs) effectively reduce the risk for @entity385 in @entity1 with @entity955 ( @entity955 ), but undertreatment and poor persistence with treatment are important problems. NOACs now provide alternatives to @entity1229 . This study compares the persistence with presently available antithrombotic treatments in @entity955 @entity1 with a CHA2DS2VASc score >= 2. METHODS: All first claims of either @entity1229 (n  =  9969), @entity3926 (n  =  2701), @entity3925 (n  =  2074), @entity5424 (n  =  1352), or @entity117 (n  =  4540) from April 2011 until December 2014, in individuals with @entity955 and CHA2DS2VASc scores of 2-9, were identified in the administrative health data register (VAL) of the Stockholm region (2.1 million inhabitants). Prescription claims were analyzed with and without multivariate analysis in relation to age, sex, prescriber category, prior OAC treatment, number of drugs, and @entity204 . RESULTS: The overall persistence with any OAC was 88.2  % (CI 87.5-88.9) at 1  year and 82.9  % (CI 81.8-83.9) at 2  years. After 1  year, the crude persistence was 85.0  % (CI 84.2-85.9) with @entity1229 , 85.9  % (CI 81.8-90.1) with @entity5424 , 74.4  % (CI 72.3-76.5) with @entity3926 , and 77.4  % (CI 74.6-80.2) with @entity3925 . Multivariate analysis confirmed significantly higher persistence with @entity1229 and @entity5424 than with @entity3926 or @entity3925 . The adherence (proportion of days covered >80  %) was above 90  % for all NOACs; significantly higher with @entity3925 compared to @entity3926 (p  <  0.001), but not compared to @entity5424 (p  =  0.14). CONCLUSIONS: After 2  years, the persistence with any anticoagulant treatment was high in @entity1 with @entity955 . Our results indicate better persistence with @entity1229 and @entity5424 than with @entity3926 or @entity3925 in regular care.

Comparison of treatment persistence with different oral anticoagulants in XXXX with @entity955 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity3926 :: ('MESH:C554682', 'Chemical') :: ['dabigatran'] @entity3925 :: ('MESH:C503223', 'Chemical') :: ['rivaroxaban'] @entity5424 :: ('MESH:C522181', 'Chemical') :: ['apixaban'] @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation', 'AF', 'non-valvular AF'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin'] @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']
@entity1 :: (9606,Species) :: ['patients']
